ro ru en


CNAM urges people with diabetes to apply for reimbursed drugs, medical devices

18:54 | 05.08.2022 Category: Social

Chisinau, Aug. 5 /MOLDPRES/- The National Medical Insurance Company (CNAM) urged patients with diabetes to benefit from insulin analogues and compensated medical devices.

According to the CNAM, starting this July, people undergoing outpatient treatment benefit from insulin analogs and medical devices for monitoring blood sugar, compensated from the mandatory medical assistance insurance funds.

Thus, diabetes patients have free access to seven international common names of insulin analogues. These preparations are released based on the prescription prescribed by the endocrinologist. In the medical institutions in the districts where there is no endocrinologist, the prescription is carried out by the doctor in charge, appointed by order of the director of the district public medical and sanitary institution.

At the same time, prescriptions for compensated medical devices - tests and lancets for glucose monitoring are issued by the family doctor. Beneficiaries, both insured and uninsured persons, can pick up medicines and medical devices from any pharmacy contracted by CNAM. Thus, the pharmacist is obliged to propose the medical device offered free of charge. If the person refuses that product, then they will be informed about the devices available, partially compensated.

Also, at the pharmacy, with the prescription prescribed by the doctor, there is the possibility to choose the drug or medical device from the list of products with different trade names and prices. If at the time of the request the drug or device is missing from the pharmacy, it must be made available to the requester within 72 hours of being addressed. Insulin analogues are 100% compensated.

Photo symbol

Any material published on the website of the Public Institution ’’A.I.S. Moldpres’’ (Moldpres News Agency) is intellectual peoperty of the Agency, protected by the copyright. The taking over or/and use of these materials will be made only with the Agency’s agreement and with compulsory reference to source.